| A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, ... Nature medicine 25 (12), 1938-1947, 2019 | 526 | 2019 |
| Discovery of piperlongumine as a potential novel lead for the development of senolytic agents Y Wang, J Chang, X Liu, X Zhang, S Zhang, X Zhang, D Zhou, G Zheng Aging (Albany NY) 8 (11), 2915, 2016 | 274 | 2016 |
| Therapy-induced senescence: opportunities to improve anticancer therapy PG Prasanna, DE Citrin, J Hildesheim, MM Ahmed, S Venkatachalam, ... JNCI: Journal of the National Cancer Institute 113 (10), 1285-1298, 2021 | 246 | 2021 |
| Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity Y He, X Zhang, J Chang, HN Kim, P Zhang, Y Wang, S Khan, X Liu, ... Nature communications 11 (1), 1996, 2020 | 224 | 2020 |
| PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics S Khan, Y He, X Zhang, Y Yuan, S Pu, Q Kong, G Zheng, D Zhou Oncogene 39 (26), 4909-4924, 2020 | 206 | 2020 |
| Vesicular monoamine transporter 2: role as a novel target for drug development G Zheng, LP Dwoskin, PA Crooks The AAPS journal 8, E682-E692, 2006 | 169 | 2006 |
| The curcumin analog EF24 is a novel senolytic agent W Li, Y He, R Zhang, G Zheng, D Zhou Aging (Albany NY) 11 (2), 771, 2019 | 140 | 2019 |
| Oxidation resistance 1 is a novel senolytic target X Zhang, S Zhang, X Liu, Y Wang, J Chang, X Zhang, SG Mackintosh, ... Aging cell 17 (4), e12780, 2018 | 119 | 2018 |
| Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity D Lv, P Pal, X Liu, Y Jia, D Thummuri, P Zhang, W Hu, J Pei, Q Zhang, ... Nature communications 12 (1), 6896, 2021 | 112 | 2021 |
| DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas Y He, R Koch, V Budamagunta, P Zhang, X Zhang, S Khan, D Thummuri, ... Journal of hematology & oncology 13, 1-13, 2020 | 101 | 2020 |
| Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies Y He, S Khan, Z Huo, D Lv, X Zhang, X Liu, Y Yuan, R Hromas, M Xu, ... Journal of Hematology & Oncology 13, 1-24, 2020 | 98 | 2020 |
| Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs Y Xiao, J Wang, LY Zhao, X Chen, G Zheng, X Zhang, D Liao Chemical Communications 56 (68), 9866-9869, 2020 | 94 | 2020 |
| Extending the analysis of nicotinic receptor antagonists with the study of α6 nicotinic receptor subunit chimeras RL Papke, LP Dwoskin, PA Crooks, G Zheng, Z Zhang, JM McIntosh, ... Neuropharmacology 54 (8), 1189-1200, 2008 | 93 | 2008 |
| Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity Y He, W Li, D Lv, X Zhang, X Zhang, YT Ortiz, V Budamagunta, J Campisi, ... Aging cell 19 (3), e13117, 2020 | 91 | 2020 |
| Cellular senescence and radiation-induced pulmonary fibrosis Y He, D Thummuri, G Zheng, P Okunieff, DE Citrin, Z Vujaskovic, D Zhou Translational Research 209, 14-21, 2019 | 91 | 2019 |
| Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity X Zhang, D Thummuri, X Liu, W Hu, P Zhang, S Khan, Y Yuan, D Zhou, ... European journal of medicinal chemistry 192, 112186, 2020 | 86 | 2020 |
| Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters DK Miller, PA Crooks, G Zheng, VP Grinevich, SD Norrholm, LP Dwoskin Journal of Pharmacology and Experimental Therapeutics 310 (3), 1035-1045, 2004 | 81 | 2004 |
| Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL X Zhang, D Thummuri, Y He, X Liu, P Zhang, D Zhou, G Zheng Chemical Communications 55 (98), 14765-14768, 2019 | 76 | 2019 |
| Stereoselective Total Synthesis of (3R,8S)-Falcarindiol, a Common Polyacetylenic Compound from Umbellifers G Zheng, W Lu, J Cai Journal of natural products 62 (4), 626-628, 1999 | 74 | 1999 |
| Overcoming cancer drug resistance utilizing PROTAC technology MR Burke, AR Smith, G Zheng Frontiers in Cell and Developmental Biology 10, 872729, 2022 | 73 | 2022 |
Daohong ZhouUniversity of Texas Health Science Center at San AntonioVerified email at uthscsa.edu